Bioxytran Inc Share Price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Bioxytran, Inc. Announces Board Changes | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 21.85M 1.71B |
---|---|---|---|---|---|
Net income 2022 | -2M -157M | Net income 2023 | -4M -313M | EV / Sales 2022 | - |
Net Debt 2022 | 1.87M 146M | Net Debt 2023 | 1.9M 149M | EV / Sales 2023 | - |
P/E ratio 2022 |
-22.4
x | P/E ratio 2023 |
-4.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.12% |
Managers | Title | Age | Since |
---|---|---|---|
David Platt
CEO | Chief Executive Officer | 71 | 28/02/18 |
Ola Soderquist
DFI | Director of Finance/CFO | 63 | - |
Leslie Ajayi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Platt
CEO | Chief Executive Officer | 71 | 28/02/18 |
Dale Conaway
BRD | Director/Board Member | 69 | 01/11/18 |
Anders Utter
BRD | Director/Board Member | 57 | 01/11/18 |
1st Jan change | Capi. | |
---|---|---|
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-0.93% | 21.83B | |
-11.11% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |